Biotech Values

[mcbio]

I still don’t get it. Unless there was a bidding war for ANDS, which seems unlikely, why would Roche move on ANDS now if the ultimate plan were to acquire ACHN later?

Well, ANDS did have a relatively tiny valuation so perhaps Roche thought it best to go ahead and acquire ANDS at this level. And ANDS and ACHN aren't mutually exclusive acquisitions since it could conceivably make sense to pair an ANDS non-nuke with an ACHN PI and/or NS5A inhibitor.